Drug · DIN 02025302
RISPERDAL
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since March 28, 2019; first marketed December 31, 1993.
- Drug Identification Number (DIN)
- 02025302
- Company (DIN owner)
- Janssen Inc.Toronto, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Risperidone N05AX08
- Class
- Human
- Record last updated
- June 25, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| RISPERIDONE | 3 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- November 12, 2014: NOC 16312Supplement to a New Drug Submission (SNDS) · Restrict indication to those patients with severe dementia of the alzheimer's type unresponsive to non-pharmacological approaches and where there is a risk of harm to others
- April 17, 1998: NOC 3147New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “risperdal”. A notice may cover another product or only some lots: read it to see what it covers.
Other DINs named RISPERDAL
- DIN 02025280 · Cancelled Post Market
- DIN 02025299 · Cancelled Post Market
- DIN 02025310 · Cancelled Post Market
- DIN 02230455 · Cancelled Post Market
- DIN 02240551 · Cancelled Post Market
- DIN 02240552 · Cancelled Post Market